



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: finacc@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2019-20

October 24, 2019

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001
BSE ID: AARTIDRUGS
BSE CODE - 524348

To,
Listing/ Compliance Department
**National Stock Exchange of India
Limited,**
"Exchange Plaza", Bandra - Kurla
Complex, Bandra (E), Mumbai - 400051
NSE SYMBOL: AARTIDRUGS

Dear Sir/Madam,

Sub: Press Release

Press release for September'19

Kindly take the same on record.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

R Deole

RUSHIKESH DEOLE

COMPANY SECRETARY & COMPLIANCE OFFICER

ICSI M.No.: A54527





Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel. : 022-2407 2249 / 2401 9025 (30 Lines)
Fax. : 022-2407 3462 / 2407 0144
Email: finacc@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Press release for September'19

In the September'19 quarter, the Company recorded consolidated quarterly revenue of Rs.477.50 Crores with year-on-year growth of 37.45%. Domestic sales of the API segment grew by approximately 46.50% and exports by 26.57%. Entire growth of the API segment is driven by volume growth. Formulation segment revenues grew by around 29.75% on year-on-year basis.

Consolidated EBITDA for the quarter ended September'19 is Rs.68.50 Crores, up by 45.45% and consolidated profit after tax for the quarter ended September'19 is Rs.32.31 Crores, up by 79.01% on year-on-year basis. Consolidated EBITDA margin improved by approximately 0.8% as compared to previous Jun'19 quarter due to higher utilization of production capacities. Company expects to improve on its gross margins in future due to better efficiencies in production. Due to continuous improvement in working capital management Company was able to further reduce its Debt/Equity ratio to 0.83 as of September'19 on consolidated basis.

Company recently expanded its anti-diabetic capacity and currently scaling up its production quantities for the same. Further brown field CAPEX would be done in the current financial year to expand few capacities in anti-inflammatory therapeutic category. Exports markets are slowly opening up for formulation division and it will drive the margins for that division.

FOR AARTI DRUGS LIMITED

ADHISH P. PATIL
CHIEF FINANCIAL OFFICER

